Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT03362606
PHASE1/PHASE2
Engineered Immune Effectors Against Ovarian Cancer
Sponsor: Shenzhen Geno-Immune Medical Institute
View on ClinicalTrials.gov
Summary
This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.
Official title: Intervention of Ovarian Cancer Based on Engineered Immune Effectors (EIEs)
Key Details
Gender
FEMALE
Age Range
10 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-06-01
Completion Date
2030-12-31
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
OC-CTLs
2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
Locations (1)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China